

**USA**  
Claims database



**HONG KONG**  
Prescription database



**AUSTRALIA**  
NSW electronic health collection




**ICELAND**

- National registers
- SAGA cohort



**UNITED KINGDOM**

- Primary care
- UK biobank
- RMT study




**NETHERLANDS**

- Lifelines
- Trails
- NeuroIMAGE



**SPAIN**

- RMT study
- MentalCat



**NORWAY**  
National registers



**SWEDEN**

- National registers
- Obesity quality registers
- Diabetes quality registers
- Cardiovascular quality register
- Twin registry
- Lifegene



**ESTONIA**  
Estonian Biobank



**DENMARK**

- National registers
- iPsych study




































 **TIMESPAN COHORTS OVERVIEW**




























## TIMESPAN COHORTS OVERVIEW

	Country, Name, WP contribution	Sample Size	Type of study	Linked data sources	Patient group	Key exposures	Outcomes relevant to TIMESPAN	Contact
  	<b>SWEDEN</b> <b>National registers</b> WP1-4 WP6	15 000 000	<b>Prescription database</b>	Health, prescription and social-economic records	ADHD and cardiometabolic disease	ADHD, Familial risk for ADHD, ADHD medication, other pharmacological treatments	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Zheng Chang <a href="mailto:zheng.chang@ki.se">zheng.chang@ki.se</a>
  	<b>SWEDEN</b> <b>Obesity quality registers</b> WP1 WP2	65 000	<b>Nation-wide quality-register of bariatric surgery</b>	Health, prescription and social-economic records, Non-pharmacological interventions, Questionnaires, Biomarkers	ADHD and bariatric surgery	ADHD, ADHD medication, other pharmacological treatments	Pharmacological and non-pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, Cardiometabolic risks	Henrik Larsson <a href="mailto:henrik.larsson@ki.se">henrik.larsson@ki.se</a>
  	<b>SWEDEN</b> <b>Diabetes quality registers</b> WP1 WP2	~300 000	<b>Nation-wide quality-register of T2DM</b>	Health, prescription and social-economic records, Non-pharmacological interventions Questionnaires, Biomarkers	ADHD and T2DM	ADHD, ADHD medication, other pharmacological treatments, physical activity	Pharmacological and non-pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, Cardiometabolic risks	Henrik Larsson <a href="mailto:henrik.larsson@ki.se">henrik.larsson@ki.se</a>
  	<b>SWEDEN</b> <b>Cardiovascular quality register</b> WP1 WP2	~200 000	<b>Nation-wide quality-register of CVD</b>	Health, prescription and social-economic records, Non-pharmacological interventions Questionnaires, Biomarkers	ADHD and CVD	ADHD, Familial risk for ADHD, ADHD medication, other pharmacological treatments	Pharmacological and non-pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, Cardiometabolic risks	Henrik Larsson <a href="mailto:henrik.larsson@ki.se">henrik.larsson@ki.se</a>
  	<b>SWEDEN</b> <b>Twin registry</b> WP1 WP4	45 000	<b>Cohort study linked with national registers</b>	Health, prescription and social-economic records, Questionnaires, Biomarkers, Genomewide data	ADHD and cardiometabolic disease	ADHD, sub-threshold ADHD, ADHD medication, other pharmacological treatments, Genomic risk factors, physical activity	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Ebba du Rietz <a href="mailto:ebba.du.rietz@ki.se">ebba.du.rietz@ki.se</a>

Country, Name, WP contribution	Sample Size	Type of study	Linked data sources	Patient group	Key exposures	Outcomes relevant to TIMESPAN	Contact
 <b>SWEDEN</b>  <b>Lifegene</b>  WP1  WP2	35 000	<b>Cohort study linked with national registers</b>	Health and social-economic records, Questionnaires, Biomarkers	ADHD and cardiometabolic disease	ADHD, sub-threshold, ADHD, ADHD medication, other pharmacological treatments, physical activity	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, Cardiometabolic risk,	Henrik Larsson <a href="mailto:henrik.larsson@ki.se">henrik.larsson@ki.se</a>
 <b>DENMARK</b>  <b>National registers</b>  WP1-3	9 850 00	<b>Prescription database</b>	Health, prescription and social-economic records	ADHD and cardiometabolic disease	ADHD, Familial risk for ADHD, ADHD medication, other pharmacological treatments	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Søren Daslgaard <a href="mailto:sdalsgaard@econ.au.dk">sdalsgaard@econ.au.dk</a>
 <b>DENMARK</b>  <b>iPsych study</b>  WP4  WP6	130 000	<b>Cohort study linked with national registers and prescription database</b>	Health, prescription and social-economic records Genomewide data	ADHD and cardiometabolic disease	ADHD, Familial risk for ADHD, ADHD medication, other pharmacological treatments, Genomic risk factors	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Ditte Demontis <a href="mailto:ditte@biomed.au.dk">ditte@biomed.au.dk</a>
 <b>US</b>  <b>Claims database</b>  WP2  WP3	67 000 000	<b>Prescription database</b>	Medical and prescription claim records	ADHD and cardiometabolic disease	ADHD, ADHD medication, other pharmacological treatments	Pharmacological guideline-indicated treatments for cardiometabolic disease, ADHD treatment discontinuity	Zheng Chang <a href="mailto:zheng.chang@ki.se">zheng.chang@ki.se</a> Brian Matthew D'Onofrio <a href="mailto:bmdonofr@indiana.edu">bmdonofr@indiana.edu</a>
 <b>NORWAY</b>  <b>National registers</b>  WP1-3	~3 000 000	<b>Prescription database</b>	Health, prescription and social-economic records	ADHD and cardiometabolic disease	ADHD, Familial risk for ADHD, ADHD medication, other pharmacological treatments,	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Kari Klungsoyr <a href="mailto:Kari.Klungsoyr@uib.no">Kari.Klungsoyr@uib.no</a>

	Country, Name, WP contribution	Sample Size	Type of study	Linked data sources	Patient group	Key exposures	Outcomes relevant to TIMESPAN	Contact
  	<b>UK</b> <b>Primary care</b> <b>WP2–3</b> <b>WP6</b>	60 000 000 (16 Mio active individuals)	<b>Prescription database</b>	Health, prescription and social-economic records	ADHD and cardiometabolic disease	ADHD, ADHD medication, other pharmacological treatments	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Ian Wong <a href="mailto:i.wong@ucl.ac.uk">i.wong@ucl.ac.uk</a>
  	<b>NETHERLANDS</b> <b>Lifelines</b> <b>WP1–2</b> <b>WP4</b> <b>WP6</b>	165 000	<b>Cohort study linked with national registers</b>	Health, prescription and social-economic health records, Questionnaires, Biomarkers, Genomewide data	ADHD and cardiometabolic disease	ADHD, sub-threshold ADHD, familial & genomic risk for ADHD, ADHD medication, other pharmacological treatments, physical activity	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Catharina Hartman <a href="mailto:c.a.hartman@umcg.nl">c.a.hartman@umcg.nl</a>
  	<b>NETHERLANDS</b> <b>Trails</b> <b>WP4</b>	2773	<b>Cohort study</b>	Questionnaires, Biomarkers, Genomewide data	ADHD and cardiometabolic disease	ADHD, sub-threshold ADHD, familial & genomic risk for ADHD, ADHD medication, other pharmacological treatments, physical activity	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Catharina Hartman <a href="mailto:c.a.hartman@umcg.nl">c.a.hartman@umcg.nl</a>
  	<b>NETHERLANDS</b> <b>NeuroIMAGE</b> <b>WP4</b>	1549	<b>Cohort study</b>	Questionnaires, Genomewide data	ADHD and cardiometabolic disease	ADHD, sub-threshold ADHD, familial & genomic risk for ADHD, ADHD medication, other pharmacological treatments, physical activity	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, ADHD treatment discontinuity	Catharina Hartman <a href="mailto:c.a.hartman@umcg.nl">c.a.hartman@umcg.nl</a>
  	<b>UK</b> <b>UK biobank</b> <b>WP4</b>	450 000	<b>Cohort study</b>	Questionnaires, Biomarkers, Genomewide data	ADHD and cardiometabolic disease	ADHD, genomic risk for ADHD	Cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality	Catharina Hartman <a href="mailto:c.a.hartman@umcg.nl">c.a.hartman@umcg.nl</a>

Country, Name, WP contribution	Sample Size	Type of study	Linked data sources	Patient group	Key exposures	Outcomes relevant to TIMESPAN	Contact
 <b>ESTONIA</b>  <b>Estonian Biobank</b>  WP1  WP6	200 000	<b>Cohort study linked with national registers</b>	Health, prescription and social-economic records, Questionnaires, Biomarkers, Genomewide data	ADHD and cardiometabolic disease	ADHD, sub-threshold ADHD, genomic risk for ADHD, other pharmacological treatments, physical activity, Genomic risk factors	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality, Cardiometabolic risk,	Kelli Lehto <a href="mailto:kelli.lehto@ut.ee">kelli.lehto@ut.ee</a>
 <b>HONG KONG</b>  WP2-3  WP6	11 000 000	<b>Prescription database</b>	Health, prescription and social-economic health records	ADHD and cardiometabolic disease	ADHD, ADHD medication, other pharmacological treatments	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality ADHD treatment discontinuity	Ian Wong <a href="mailto:i.wong@ucl.ac.uk">i.wong@ucl.ac.uk</a> Patrick Ip <a href="mailto:patricip@hku.hk">patricip@hku.hk</a>
 <b>ICELAND</b>  <b>National registers</b>  WP1-3	260 000	<b>Prescription database</b>	Health, prescription and social-economic records	ADHD and cardiometabolic disease	ADHD, ADHD medication, other pharmacological treatments	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality ADHD treatment discontinuity	Helga Zoega <a href="mailto:h.zoega@unsw.edu.au">h.zoega@unsw.edu.au</a> Harpa Lind Jónsdóttir <a href="mailto:harpalj@hi.is">harpalj@hi.is</a>
 <b>ICELAND</b>  <b>SAGA cohort</b>  WP1-3	32 000 females	<b>Cohort study linked with national registers</b>	Health, prescription and social-economic health records, Questionnaires	ADHD and cardiometabolic disease	ADHD, sub-threshold ADHD, ADHD medication, other pharmacological treatments	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality ADHD treatment discontinuity	Helga Zoega <a href="mailto:h.zoega@unsw.edu.au">h.zoega@unsw.edu.au</a> Harpa Lind Jónsdóttir <a href="mailto:harpalj@hi.is">harpalj@hi.is</a>
 <b>AUSTRALIA</b>  <b>NSW – electronic health collection</b>  WP1-3	7 500 000	<b>Prescription database</b>	Health, prescription and social-economic health records	ADHD and cardiometabolic disease	ADHD, ADHD medication, other pharmacological treatments	Pharmacological guideline-indicated treatments for cardiometabolic disease, psychosocial and well-being outcomes, morbidity, mortality ADHD treatment discontinuity	Helga Zoega <a href="mailto:h.zoega@unsw.edu.au">h.zoega@unsw.edu.au</a>

Country, Name, WP contribution	Sample Size	Type of study	Linked data sources	Patient group	Key exposures	Outcomes relevant to TIMESPAN	Contact
   <b>UK</b> <b>RMT study</b> <b>WP5</b>	150	<b>Prospective observational cohort study</b>	ART (ADHD Remote Technology) active and passive app, EmbracePlus	ADHD	ADHD, ADHD medication, physical activity	ADHD treatment discontinuity and adverse effects, cardiometabolic risks (heart rate, blood pressure, weight, smoking, alcohol use, physiological stress response, sleep), psychiatric comorbidities (antisocial behaviour, anxiety, depression, substance use).	Jonna Kuntsi <a href="mailto:jonna.kuntsi@kcl.ac.uk">jonna.kuntsi@kcl.ac.uk</a> Richard Dobsen <a href="mailto:richard.j.dobson@kcl.ac.uk">richard.j.dobson@kcl.ac.uk</a>
   <b>SPAIN</b> <b>RMT study</b> <b>WP5</b>	150	<b>Prospective observational cohort study</b>	ART passive and active app, EmbracePlus	ADHD	ADHD, ADHD medication, physical activity	Same as in UK RMT study (see row above)	Josep Antoni Ramos-Quiroga <a href="mailto:jaramos@vhebron.net">jaramos@vhebron.net</a>
   <b>SPAIN</b> <b>MentalCat</b> <b>WP4</b>	1500	<b>Clinical study</b>	Questionnaires, Genomewide data	ADHD	Genomic risk factors	ADHD treatment discontinuity, treatment response, side effects	Josep Antoni Ramos-Quiroga <a href="mailto:jaramos@vhebron.net">jaramos@vhebron.net</a>